We demonstrated that RLɉ1-specific cytotoxic T lymphocytes (CTL) were generated in spleen cells from the tumor-rejected CB6F 1 mice on in vitro stimulation with L d -binding pRL1a peptide. We showed that CD4 T cells and antigen-presenting cells were necessary for CTL generation. 
Introduction
Tumor rejection antigen has been demonstrated on BALB/c radiation-induced leukemia RLɉ1 cells (1-5). Inocula of 5ϫ10 5 RLɉ1 cells into BALB/c mice continued to grow and the mice were killed by the tumor in 3-4 weeks, but the same inocula in CB6F 1 mice regressed after initial growth of the tumor (1). The inocula at a lower dose (~1ϫ10 5 ) in BALB/c mice often resulted in tumor regression. Regression of the tumor was blocked by in vivo depletion of CD8 T cells but not CD4 T cells (2,3). Cytotoxic T lymphocytes (CTL) were generated in vitro in spleen cells from BALB/c and CB6F 1 mice in which the tumor was growing or had regressed (4) . These findings indicated that the tumor rejection antigen recognized by CTL was present on RLɉ1 tumor cells and that CB6F 1 mice were better responders than BALB/c mice. Recently, we identified the tumor rejection antigen peptides on RLɉ1 cells that were recognized by specific CTL (5).
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Activation of CD4 T cells in the tumor-rejected mice was not against the tumor antigen, but appeared to be against the self in an I-A d -restricted manner.
Methods

Mice
BALB/c (H-2 d ), C57BL/6 (B6) (H-2 b ), (BALB/cϫB6)F 1 (CB6F 1 ) and athymic BALB/c mice were bred in our laboratory animal center.
Tumors
RLɉ1 is a BALB/c radiation-induced leukemia (1). MOPC-70A is a BALB/c plasmacytoma (8) . EL4 is a chemically induced leukemia of C57BL origin (9) . These tumors were maintained by tissue culture and as ascites form. For immunization of mice, tumor lines maintained by in vivo passage were used. P815 is a DBA/2 methylcholanthrene-induced mastocytoma (10) . A20.2J is a BALB/c B cell lymphoma (11) and was obtained from the ATCC (Rockville, MD). These tumors were maintained by tissue culture. Antigens pRL1a (IPGLPLSL) is the tumor rejection antigen peptide recognized by RLɉ1-specific CTL and pRL1b (SIIPGLPLSL) is its precursor peptide (5). pRL1b(-) (SIIPGLPL), derived from pRL1b, was used as a control. Chicken ovalbumin (OVA) peptide (323-339) (ISQAVHAAHAEINEAGR) is an I-A b/d -binding peptide recognized by T cell hybridoma . λ repressor peptide (LEDARRLKAIYEKKK) was described previously (13) . These peptides were synthesized by standard solid-phase method using Fmoc chemistry in an 430A peptide synthesizer (Applied Biosystems, Foster City, CA). Cleavage of the peptide from the resin and removal of the side chainprotecting groups were carried out using trifluoroacetic acid. The peptides were purified by reversed-phase HPLC (model 151A; Applied Biosystems) on a preparative C8 column (10ϫ100 mm, 20 µm particle size; Applied Biosystems) in 0.1% trifluoroacetic acid with an acetonitrile gradient. Chicken OVA was obtained from Sigma (St Louis, MO). For preparation of the lysate, RLɉ1 cells were lysed by freezing and thawing 3 times as described (14) . mAb Anti-L3T4 (CD4) mAb, a rat IgG2b antibody produced by hybridoma GK1.5 (15) , was provided by Dr F. Fitch (University of Chicago, Chicago, IL). Anti-Lyt-2.2 (CD8) mAb, a mouse IgG2a antibody produced by hybridoma 19/178, was provided by Dr U. Hä mmerling (Memorial Sloan-Kettering Cancer Center, New York) (16) . Anti-H-2K d and anti-H-2D d mAb are mouse IgG2a antibodies produced by hybridomas HB159 and HB102 respectively. Both mAb were obtained from ATCC. Anti-H-2L d mAb is a mouse IgG2a antibody produced by hybridoma 30-5-7s (17) . Anti-I-A d mAb is a mouse IgG2b antibody produced by hybridoma MK-D6 (18) . Anti-I-E k/d mAb is a mouse IgG2b antibody produced by hybridoma ISCR3 (19) . These mAb were provided by Dr N. Shinohara (Kitasato University, Sagamihara, Japan).
In vitro generation of CTL CB6F 1 mice were inoculated s.c. in the back with 5ϫ10 5 RLɉ1 cells. After regression of the tumor, spleen cells (5ϫ10 6 ) were prepared and cultured with various concentrations of peptide or with mitomycin C (MMC)-treated RLɉ1 cells (5ϫ10 5 ) in 24-well tissue culture plates (Falcon 3047; Becton Dickinson, Franklin Lakes, NJ) for 5 days at 37°C in 5% CO 2 air. For generation of allogeneic CTL, BALB/c or C57BL/6 (B6) spleen cells were cultured with MMC-treated stimulator spleen cells in 24-well tissue culture plates for 5 days at 37°C in 5% CO 2 air. The culture medium was RPMI 1640 (Gibco, Grand Island, NY) containing 10% FCS, 2 mM L-glutamine, 100 U/ml of penicillin, 100 µg/ml of streptomycin and 5ϫ 10 -5 M 2-mercaptoethanol. MMC treatment was done by incubating cells with MMC at a concentration of 50 µg/ml for 30 min at 37°C. For inhibition of CTL generation, various mAb were added to the 5 day culture.
Cell-mediated cytotoxicity assay
A conventional 4 h 51 Cr-release assay was performed as described previously (4) . Briefly, tumor cells were labeled with 1.85 MBq of Na 2 51 CrO 4 (New England Nuclear, Boston, MA) for 2 h at 37°C in 5% CO 2 air. They were then washed and used as target cells. For peptide pulsing, 10 -5 M peptide was added to P815 cells (2ϫ10 6 ) during labeling. In direct assays, 5ϫ10 3 labeled target cells (100 µl) were incubated with the effector cell suspension (100 µl). In antibody blocking assays, serially diluted antibody (50 µl) was added to the cultures of effector cells (50 µl) and labeled target cells (50 µl). After incubation for 4 h at 37°C in 5% CO 2 air, the supernatants (100 µl) were removed and their radioactivity was measured. The percentage of specific lysis was calcu- 
Depletion of APC
Spleen cells (2ϫ10 8 ) were incubated for 1 h at 37°C in a 10 ml syringe packed with 0.6 g nylon wool (Wako Pure Chemical Industries, Osaka, Japan). Yields of Thy-1 ϩ cells in the eluate were 78.5-90.5%.
Paraformaldehyde fixation
Cells were fixed in 0.1% paraformaldehyde in PBS for 30 min on ice and were washed 3 times before use.
T cell proliferation assay
In vitro CD8-depleted responder spleen cells from RLɉ1-rejected CB6F 1 mice were stimulated with MMC-treated RLɉ1 cells, RLɉ1 lysate or pRL1a peptide in 96-well plates (Falcon 3072; Becton Dickinson) for 4 days at 37°C in 5% CO 2 air. The cells were then harvested and [ 3 H]thymidine uptake was measured.
Production of IL-2
Responder cells were cultured with or without antigen for 1-4 days. For the inhibition assay, cells were cultured in the presence of mAb. The amount of IL-2 in the culture supernatant was measured using the IL-2-dependent cell line NRB (20) . Briefly, NRB cells (5ϫ10 3 ) were incubated with culture supernatant for 24 h and then [ 3 H]thymidine uptake was measured.
Competitive inhibition of the peptide binding to I-A d molecule Assays were described previously (21) . B cell lymphoma A20.2J cells were fixed with 0.1% PFA for 30 min. Various concentrations of competitor peptides were added to the fixed A20.2J (1ϫ10 5 ) cells and incubated for 30 min, then 10 -5 M OVA peptide was added to the 96-well plate (Falcon 3077; Becton Dickinson). T cell hybridoma DO-11.10 cells (1ϫ10 5 ) were then added and incubated for 24 h at 37°C in 5% CO 2 air. The response of DO-11.10 was assessed by measuring the amount of IL-2 secreted.
Results
Generation of CTL in spleen cells from RLɉ1-rejected CB6F 1 mice on in vitro stimulation with the pRL1a peptide
The inocula of 5ϫ10 5 RLɉ1 cells into CB6F 1 mice grew into tumors and then regressed. Spleen cells (5ϫ10 6 ) obtained from the tumor-rejected mice were cultured with the pRL1a peptide for 5 days. As shown in Fig. 1 , cytotoxicity was generated against RLɉ1 and pRL1a-pulsed P815, but not against the P815 target, at an optimal concentration of 10 -6 M pRL1a. The extent of cytotoxicity generated on stimulation with the pRL1a peptide was generally less than that generated on stimulation with MMC-treated RLɉ1 cells. Spleen cells cultured with control peptide (SIIPGLPL) or alone showed only marginal cytotoxicity. The cytotoxicity generated on stimulation with the pRL1a peptide was blocked by the addition of anti-Lyt-2.2 (CD8) mAb and anti-L d mAb (30-5-7s), but not anti-L3T4 (CD4) mAb (GK1.5), anti-K d mAb (HB159) or anti-D d mAb (HB102) to the assay culture (data not shown).
Requirement of CD4 T cells for generation of CTL on in vitro stimulation with pRL1a peptide
We investigated the requirement of CD4 T cells for the generation of CTL on in vitro stimulation with the L d -binding pRL1a peptide. As shown in Fig. 2 , the generation of cytotoxicity was diminished by treatment of spleen cells from RLɉ1-rejected CB6F 1 mice with anti-L3T4 (CD4) mAb (GK1.5) and complement before culturing with the pRL1a peptide. The generation of cytotoxicity was also diminished by the treatment of the tumor-rejected CB6F 1 mice with anti-L3T4 The requirement of CD4 T cells was observed with a range of peptide concentrations (Fig. 3A) . The addition of in vitro CD8-depleted spleen cells from RLɉ1-rejected mice, but not naive CB6F 1 mice, to in vitro CD4-depleted spleen cells from the rejected mice reconstituted the generation of cytotoxicity on in vitro stimulation with the pRL1a peptide (Fig. 3B) . Moreover, the addition of rIL-2 (Ͼ0.25 U/ml) to the culture of in vitro CD4-depleted spleen cells also reconstituted the generation of cytotoxicity (Fig. 3C) . No cytotoxicity against the P815 target was observed with rIL-2 (data not shown). To investigate the requirement of APC for in vitro generation of CTL, spleen cells from RLɉ1-rejected CB6F 1 mice were passed through a nylon wool column and then stimulated with the pRL1a peptide in vitro. As shown in Fig. 3(D) , no cytotoxicity was generated. Cytotoxicity was generated by the addition of MMC-treated, but not PFA-treated, peritoneal exudate cells (PEC) from naive CB6F 1 mice to nylon woolpassed spleen cells. The results were essentially similar on in vitro stimulation with MMC-treated RLɉ1 cells (data not shown).
Inhibition of CTL generation by anti-H-2 class II mAb
The inhibition of CTL generation by anti-H-2 class II mAb was then investigated. Purified anti-I-A d mAb (MK-D6) and anti-I- , no inhibition by the pRL1a peptide was observed (Fig. 5) . 1ϫ10 5 ) were then added and incubated for 24 h. The IL-2 content of the culture supernatant was measured using IL-2-dependent cell line NRB as described (20) .
Proliferation of CD4 T cells and IL-2 production from them in spleen cells from RLɉ1-rejected CB6F 1 mice against self, but not tumor antigen
We investigated the proliferation of CD4 T cells and IL-2 production from them in spleen cells from RLɉ1-rejected CB6F 1 mice. As shown in Fig. 6 , no specific proliferative response was observed with differing amounts of in vitro CD8-depleted spleen cells on a range of MMC-treated RLɉ1 cells, RLɉ1 lysate or the pRL1a peptide. Rather, significant proliferation was observed with the responder spleen cells cultured alone. The response was abrogated by in vitro depletion of APC and restored by adding PEC from either the tumor-rejected or naive CB6F 1 mice to them (Fig. 6D) .
As shown in Fig. 7 , a significant amount of IL-2 was detected in the culture supernatant of in vitro CD8-but not CD4-depleted spleen cells from RLɉ1-rejected CB6F 1 mice. IL-2 production was abrogated by passing the spleen cells through a nylon wool column and restored by adding PEC from either the tumor-rejected or untreated CB6F 1 mice to them. IL-2 production by in vitro CD8-depleted spleen cells was blocked by the addition of purified anti-I-A d mAb (MK-D6), but not anti-I-E k/d mAb (ISCR3) to the culture (data not shown).
Generation of CTL against pRL1a peptide in in vitro CD4-depleted spleen cells from RLɉ1-rejected CB6F 1 mice by adding CD8-depleted spleen cells from CB6F 1 mice that had rejected other tumors
We further investigated whether the autoreactive proliferation of CD4 T cells similarly took place in mice that had rejected other tumors and could also help generation of pRL1a-specific CTL. As shown in Fig. 8 , the addition of in vitro CD8-depleted spleen cells from CB6F 1 mice that had rejected EL4 or MOPC-70A to the culture of in vitro CD4-depleted spleen cells from RLɉ1-rejected CB6F 1 mice generated CTL on stimulation with the pRL1a peptide.
Discussion
In this study, we demonstrated that RLɉ1-specific CTL were generated in spleen cells from the tumor-rejected CB6F 1 mice on in vitro stimulation with the pRL1a peptide. We showed that CD4 T cells and APC were necessary for in vitro CTL generation. The addition of rIL-2 to the culture of in vitro CD4-depleted spleen cells from tumor-rejected CB6F 1 mice reconstituted CTL generation, suggesting that the IL-2 produced by CD4 T cells is crucial. Furthermore, generation of CTL was blocked by the addition of anti-I-A d mAb, but not anti-I-E k/d mAb, to the culture. These findings may suggest that the L d -binding octamer pRL1a peptide also binds to the Fig. 7 . IL-2 production. Spleen cells (3ϫ10 6 ) from RLɉ1-rejected (A) or naive (B) CB6F 1 mice treated with anti-L3T4 (CD4) mAb (GK1.5) or anti-Lyt-2.2 (CD8) mAb plus complement, passed through a nylon wool column or passed through a nylon wool column and mixed with 5ϫ10 5 PEC from naive CB6F 1 mice, were cultured in 24-well plates. Four days after culture, the IL-2 content of the supernatant was measured using the IL-2-dependent cell line NRB as described (20) .
I-A d molecule on APC and stimulates CD4 T cells to produce IL-2. However, no such binding could be demonstrated by competitive inhibition of I-A d -restricted recognition of the OVA peptide by CD4 T cell hybridoma DO-11.10. Moreover, no specific proliferative response or IL-2 production was observed with CD4 T cells in spleen cells from the tumorrejected mice on stimulation with a range of MMC-treated RLɉ1 cells, RLɉ1 lysate or the pRL1a peptide. Rather, the activation of autoreactive CD4 T cells and the IL-2 production by them were observed in spleen cells from the tumor-rejected CB6F 1 mice, which appeared to be responsible for CTL generation. The finding that CD4 T cells from CB6F 1 mice that had rejected other tumors such as EL4 or MOPC-70A also helped the generation of pRL1a-specific CTL confirmed the involvement of autoreactive CD4 T cells in CTL generation against the pRL1a peptide.
It was reported that murine thymocytes and splenic T cells showed a proliferative response against syngeneic APC (22) (23) (24) (25) . A similar observation was also made on human T cells from peripheral blood lymphocytes (26) . These syngeneic mixed lymphocyte responses appeared to be the basis of IL-2 production by CD4 T cells required for CTL generation. The response involved the MHC class II antigen and was independent of FCS (24, 25) . In this study, for immunization of mice, we used tumor cell lines maintained by in vivo passage as ascites form, suggesting that the involvement of FCS was unlikely. The proliferation of CD4 T cells and the IL-2 production by them were also observed with those from unsensitized mice. However, the extent of production from the tumor-rejected CB6F 1 mice was 2-to 5-fold greater than that from naive CB6F 1 mice. CD4 T cells in the tumor-rejected CB6F 1 mice must somehow be activated against the self antigen and show efficient proliferation and IL-2 production, thus explaining the requirement of in vivo sensitization with the tumor itself. It is unknown why autoreactive CD4 T cells were activated in tumor rejection in this study. Activation of autoreactive CD4 T cells could be due to direct activation by the self antigen overexpressed on APC, or bystander activation (27, 28) during rejection of large tumor mass. Previously, Kuribayashi et al. (29) established a CTLL-D4 cell line comprising Lyt-1 ϩ 2 -3 -and Lyt-1 Ϯ 2 ϩ 3 ϩ populations from RLɉ1-rejected CB6F 1 spleen cells by in vitro stimulation with tumor cells without exogenously added IL-2. Adoptive transfer of CTLL-D4 was effective for tumor rejection only in the presence of the Lyt-1 ϩ 2 -3 -population of which proliferative response was shown to be against the self, but not the tumor antigen (30) . These findings were consistent with our findings. The finding that CTL were generated in CD4-depleted, RLɉ1-rejected CB6F 1 spleen cells on stimulation with MMC-treated RLɉ1 cells (as shown in Fig. 2 ) indicated that strongly antigenic tumor cells were capable of activating CD8 precursor CTL even without help from CD4 T cells. RLɉ1 did not produce IL-2 in culture. Thus, autoreactive CD4 T cells optimized the generation of CD8 CTL.
In vitro CTL induction following vaccination with class I-binding short epitope peptides alone was generally difficult. This is probably due to the low immunogenicity of the peptide and failure to activate CD4 T cells due to lack of the helper epitope. For binding to the class II antigen, peptide length was shown to be critical (31, 32) and an octamer or a nonamer peptide does not generally bind to class II antigens. Thus, for vaccination with viral antigen peptides, long peptides (15-20mer) were used which potentially included class II-binding helper epitopes for CD4 activation (33, 34) . Recently, however, there were some reports which showed CTL induction by class I-binding short peptides derived from viruses or bacteria which appeared to be strongly immunogenic (35) (36) (37) . This suggested that the CD4 requirement was inversely related to the antigenic strength of the peptide used.
The requirement of CD4 T cells for in vitro CTL generation in spleen cells from mice without in vivo sensitization on stimulation with MHC class I-binding peptide has been shown previously (38) . Endogenous p2Ca peptide derived from oxoglutarate dehydrogenase is an octamer peptide which binds to L d molecules and is recognized by allogeneic L dspecific 2C CTL line (39) . We and others showed that the p2Ca peptide is capable of generating CTL in in vitro primary cultures of spleen cells (38, 40) . CD4 T cells and APC were both required for generation of CTL. Furthermore, anti-I-A d mAb, but not anti-I-E d mAb, blocked CTL induction. It could be possible that the peptide was bound to H-2 class II molecules. However, direct proof of the binding of the peptide to class II molecule or that of any specific proliferative response of CD4 T cells or IL-2 production from them is lacking. Rather, it could be possible that activation of autoreactive CD4 T cells occurred in spleen cells from naive mice (see above) providing enough help for CD8 T cells to react against such a strongly antigenic peptide. Cytokines such as IL-1 secreted from macrophages which endocytosed the high concentration (~10 -6 M) of peptide used for in vitro stimulation would facilitate the activation of CD4 T cells.
